APN401
invIOs
[]
 today at #aacr23 we shared promising clinical data on our lead #celltherapy candidate, apn401, underscoring its potential as a novel #cancer #immunotherapy. full press release on our website: 
Innovative immuno-oncology means developing tomorrow's cancer therapies, today.